Chengdu New Radiomedicine Technology Co. LTD.
Quick facts
Phase 3 pipeline
- cTACE · Oncology
cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery. - NRT6003 Injection · Oncology
NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Chengdu New Radiomedicine Technology Co. LTD. portfolio CI brief
- Chengdu New Radiomedicine Technology Co. LTD. pipeline updates RSS
Frequently asked questions about Chengdu New Radiomedicine Technology Co. LTD.
What is Chengdu New Radiomedicine Technology Co. LTD.'s pipeline?
Chengdu New Radiomedicine Technology Co. LTD. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include cTACE, NRT6003 Injection.
Related
- Sector hub: All tracked pharma companies